lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   12 Trials   12 Trials   1286 News 


«12345678910111213...1415»
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    #venvanseFake (Twitter) -  Jun 17, 2021   
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Journal:  Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. (Pubmed Central) -  Jun 11, 2021   
    P2
    In preschool-aged children with ADHD, LDX was generally well tolerated and reduced ADHD symptoms, consistent with observations in children 6-17 years of age. Based on these findings, a starting LDX dose as low as 5 mg in phase 3 studies in preschool-aged children is supported.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Review, Journal:  Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. (Pubmed Central) -  Jun 8, 2021   
    Patients have seen statistically significant improvements in their ADHD symptomatology in the classroom environment, health related quality of life, and their overall behavior in comparison to placebo, atomoxetine, and OROS-MPH. However, clinical judgment should be utilized when prescribing LDX due to patient specific needs and the side effect profile.
  • ||||||||||  Adhansia XR (methylphenidate extended release capsule) / Purdue
    Enrollment closed, Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world:  reFOQus: Real World Evidence of the Efficacy and Safety of FOQUEST (clinicaltrials.gov) -  May 19, 2021   
    P4,  N=236, Active, not recruiting, 
    LDX was associated with long-term reductions in ADHD symptoms and severity. Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Jul 2021 | Trial primary completion date: Aug 2020 --> Jul 2021
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Journal:  Binge Eating Disorder: A Psychiatrist's Commentary on Clinical Considerations. (Pubmed Central) -  May 15, 2021   
    Additional medication choices approved by the US Food and Drug Administration for the treatment of BED are needed. Moving forward, opportunities to leverage modern technology to broaden access to treatment are highly desirable.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Clinical, Journal:  Abnormal movements and diaphragmatic flutter in a case of suspected induced illness. (Pubmed Central) -  May 15, 2021   
    The patient underwent extensive investigation for her symptoms and, after some delay in waiting for initial results before considering a urine drug screen, she was ultimately found to have lisdexamfetamine and clonidine in her urine drug screen. Her symptoms subsequently resolved after her mother's visits were restricted.
  • ||||||||||  amphetamine / Generic mfg.
    [VIRTUAL] Combined Impact of Prenatal MDMA Exposure and Overcrowding on Intermittent Explosive Disorder () -  May 2, 2021 - Abstract #APA2021APA_398;    
    We present the case of a 10-year-old boy with past psychiatric history of ADHD, on Vyvanse who was hospitalized for aggression, attempting to drown his sibling in a swimming pool...The Vyvance was discontinued due to ineffectiveness, side effect and due to possibility that the amphetamine may be activating and making him more irritable...The patient didn’t demonstrate any key signs of ADHD on unit such as, inattention, hyperactivity or impulsivity, which is why he was on only Abilify monotherapy...Lee et al discussed that aversive parenting associated with the development of IED (8). Additionally, unfavorable childhood environment and family history of ongoing substance use may have perpetuated his aggression.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    New trial:  Drug Use Study With VYVANSE (clinicaltrials.gov) -  Apr 28, 2021   
    P,  N=150, Active, not recruiting, 
  • ||||||||||  Edronax (reboxetine) / Pfizer
    [VIRTUAL] Evidence-based therapeutic management of binge-eating disorder (e-Poster Gallery) -  Apr 26, 2021 - Abstract #EPA2021EPA_1414;    
    Lisdexamfetamine dimesylate is the only FDA approved drug for this indication, as dasotraline was rejected by FDA and its research discontinued by the manufacturer. Fluoxetine, sertraline, escitalopram, duloxetine, bupropion, atomoxetine, reboxetine, armodafinil, disulfiram, baclofen, zonisamide, lamotrigine, topiramate, samidorphan, liraglutid, and orlistat need more trials in order to validate their efficacy, especially on long term.  Conclusions There is only one drug currently FDA approved for this indication, lisdexamfetamine, and a number of psychotherapies, with CBT and IPT being the most supported by evidence.
  • ||||||||||  methylphenidate tablet / Generic mfg., atomoxetine / Generic mfg., amphetamine / Generic mfg.
    [VIRTUAL] Impact of Implementation of Stimulant Medication Order Menu on Psychostimulant Prescribing () -  Apr 4, 2021 - Abstract #CPNP2021CPNP_198;    
    Data that will be evaluated includes: prescription type (new start vs continuation), substance use disorder history, specific stimulant medication prescribed, and prescriber service. Data will be evaluated to identify areas where additional education and pharmacist interventions can be implemented to help improve patient safety and outcomes.
  • ||||||||||  abiraterone acetate / Generic mfg., danazol oral / Generic mfg.
    Review, Journal:  Drug-induced endocrine blood pressure elevation. (Pubmed Central) -  Mar 16, 2021   
    Drugs with known adverse effects but where benefits outweigh their risks, drug candidates or market withdrawals are reviewed. Finally, potential therapeutic strategies are discussed.
  • ||||||||||  amphetamine / Generic mfg.
    Preclinical, Journal:  Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia. (Pubmed Central) -  Mar 4, 2021   
    Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), were administered to NWR animals aiming to mimic the human first episode of psychosis, and the effects on serum lipids were also evaluated...These data open new insights for understanding the potential influence of the treatment with typical or atypical antipsychotics on circulating lipids. This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial primary completion date:  AGUALIS: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents (clinicaltrials.gov) -  Feb 21, 2021   
    P=N/A,  N=20, Recruiting, 
    This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022